Cognition Therapeutics, Inc.
NASDAQ:CGTXBiotechnology
-$0.01 today
- Market cap
- $57.06M
- Beta
- 1.75
- P/E (TTM)
- -6.4
- EPS (TTM)
- -$0.22
Volume 0.34M
Average 1.23M
CGTX Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
Cognition Therapeutics, Inc.NASDAQ: CGTX
Common Stock · Q1 FY2026 · quarter ended Mar 2026
Common stock rises 45.2% from a year ago
Common stock stood at $90K at the end of Q1 FY2026, up 45.2% from a year earlier and up 0.0% from the prior quarter. Over 3 fiscal years it compounded at +45.9% a year.
Context
- Common stock amounted to 0.2% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Common stock increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether common stock keeps rising in the next quarterly balance sheet after a +45.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 90K USD
- Year-over-year change
- +50.0%
- 4-year CAGR
- +42.2%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 90K | +50.0% |
| FY2024 | 2024-12-31 | 60K | +87.5% |
| FY2023 | 2023-12-31 | 32K | +10.3% |
| FY2022 | 2022-12-31 | 29K | +31.8% |
| FY2021 | 2021-12-31 | 22K | — |
Common Stock vs competitors
How CGTX compares with its peers on the latest reported figures
- CGTX's Mar 2026 common stock of $90K is the 2nd highest of the 8 companies compared; the peer median is $10K.
- Its year-over-year change of +45.2% is the highest of 8, against a peer median of +11.1%.
- Common stock amounts to 0.2% of total assets for CGTX, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $385K | +44.7% | -51.3% | 0.2% | |
| Mar 2026 | $90K | +45.2% | +45.9% | 0.2% | |
| Mar 2026 | $58K | +3.6% | +2.5% | 0.1% | |
| Mar 2026 | $14.67K | +11.2% | +3.6% | 0.1% | |
| Mar 2026 | $10K | +11.1% | -56.9% | 0.0% | |
IRDOpus Genetics, Inc. | Mar 2026 | $7K | +40.0% | +51.8% | 0.0% |
| Mar 2026 | $1K | +0.0% | — | 0.0% | |
| Mar 2026 | $1K | +0.0% | +0.0% | 0.0% | |
| Peer median (excluding CGTX) | $10K | +11.1% | +1.3% | 0.0% | |
Competitors are the stored peer set for CGTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 54.72M | 41.56M | 29.92M | 25.01M | 36.81M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 2.27M | 3.67M | 1.28M | 2.69M | 9.92M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 11K | 0 | 3.02M | 0 | 1.26M |
| Total Current Assets | 58.99M | 47.65M | 34.22M | 29.56M | 47.99M |
| Property, Plant & Equipment (Net) | 145K | 1.05M | 941K | 679K | 399K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 1.73M | 0 | 0 | 0 |
| Total Non-current Assets | 145K | 2.78M | 941K | 679K | 399K |
| Total Assets | 59.14M | 50.43M | 35.16M | 30.23M | 48.39M |
| Account Payables | 4.17M | 3.22M | 3.7M | 1.98M | 1.12M |
| Short-term Debt | 0 | 634K | 544K | 279K | 307K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 753K | 1.7M | 1.7M | 1.07M | 367K |
| Other Current Liabilities | 2.48M | 870K | 1.17M | 1.53M | 1.57M |
| Total Current Liabilities | 7.86M | 7.8M | 10.17M | 11.14M | 13.92M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | (695K) | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 1.69M | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 695K | 0 | 0 | 0 |
| Total Non-current Liabilities | 0 | 2.38M | 520K | 342K | 195K |
| Total Liabilities | 7.86M | 10.18M | 10.69M | 11.48M | 14.12M |
| Common Stock | 22K | 29K | 32K | 60K | 90K |
| Retained Earnings | (94M) | (115.4M) | (141.19M) | (175.16M) | (198.65M) |
| Accumulated OCI | (198K) | (199K) | (195K) | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 51.27M | 40.25M | 24.47M | 18.75M | 34.27M |
| Total Debt | 0 | 1.48M | 1.24M | 814K | 638K |
| Net Debt | (54.72M) | (40.08M) | (28.68M) | (24.2M) | (36.17M) |
Cognition Therapeutics, Inc.
NASDAQ:CGTX
Intrinsic Alpha fair value
Locked
Current Price
$0.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.